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Abstract
Purpose—Several pathologic staging systems characterize residual tumor in patients undergoing 
neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted 
by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two 
other systems of post-neoadjuvant pathologic tumor staging—Residual Cancer Burden (RCB) and 
the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC)—
have been developed to characterize residual tumors when patients do not achieve pCR. The 
optimal system, and the ways in which these systems complement each other, have not been fully 
determined.
Methods—Using data from the I-SPY 1 TRIAL, we compared pCR, RCB and yAJCC as 
predictors of early recurrence-free survival (RFS) to identify ways to improve post-neoadjuvant 
pathologic evaluation.
Results—Among 162 patients assessed, pCR identified patients at lowest risk of recurrence, 
while RCB and yAJCC identified patients at highest risk. Hormone-receptor (HR) and HER2 
subtypes further improved risk prediction. Recursive partitioning indicated that triple negative or 
HER2+ patients with yAJCC III or RCB 3 have the highest recurrence risk, with an RFS of 27%. 
Our analysis also highlighted discrepancies between RCB and yAJCC stratification: 31% of 
patients had discrepant RCB and yAJCC scores. We identified differential treatment of lymph 
node involvement and tumor cellularity as drivers of these discrepancies.
Conclusions—These data indicate that there is benefit to reporting both RCB and yAJCC for 
patients in order to identify those at highest risk of relapse.
Keywords
Breast neoplasm; neoadjuvant therapy; local neoplasm recurrence; residual neoplasm; cancer 
staging; lymph nodes; disease-free survival; lymph nodes; Residual Cancer Burden; pathologic 
complete response
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Several pathologic staging systems have been developed to risk-stratify patients following 
completion of neoadjuvant chemotherapy for breast cancer (Table 1). The most commonly 
used and extensively evaluated system—pathologic complete response (pCR) [1, 3, 4, 10, 
14]—is defined as absence of invasive cancer in breast or lymph node tissue after 
completion of neoadjuvant chemotherapy [6]. Patients with this response to chemotherapy 
have a demonstrably lower risk of tumor recurrence than patients with residual carcinoma 
[18]. When accompanied by results from definitive trials, the Food and Drug Administration 
(FDA) recognizes pCR as an endpoint for granting accelerated approval in neoadjuvant 
chemotherapy trials in order to shorten the time to evaluate new chemotherapeutic agents [5, 
13]. However, by definition, pCR does not distinguish among patients with residual tumor. 
Two other staging systems—Residual Cancer Burden (RCB) and the American Joint 
Committee on Cancer post-neoadjuvant staging (yAJCC)—do stratify patients with residual 
cancer.
RCB reports a score based on the fraction of the tumor bed area that contains invasive 
carcinoma excluding in situ disease (“cellularity”), the dimensions of the tumor bed 
containing residual cancer, the number of residually-positive lymph nodes, and the longest 
diameter of the largest residual nodal metastasis [16]. Raw scores are then categorized into 
RCB classes using pre-defined cut-points, with a score of 0 representing pCR and scores 1–3 
representing progressively greater extents of residual cancer. In addition, RCB has been 
shown to provide prognostic value independent of yAJCC stage for patients with post-
treatment stage II and III disease [16].
The post-neoadjuvant yAJCC staging system has also been demonstrated to have prognostic 
value [15]. yAJCC parses patients into five groups and nine subgroups based on the extent 
and characteristics of residual disease [2]. The system considers three parameters for 
pathologic staging: tumor in the breast, tumor in local lymph nodes, and metastases. 
Residual tumor in the breast (ypT) is determined by pathologic size and extension, as well as 
chest wall or skin invasion and pre-treatment inflammatory carcinoma. Residual nodal 
involvement (ypN) is determined primarily by number of positive lymph nodes, although 
characteristics of these nodes (e.g. matted or fixed) also affect this score. Finally, yM 
designates distant metastases, and is typically established clinically before treatment. A 
combined ypTNM designation yields an overall yAJCC stage, ranging from 0–IV, with 
subgroups within stages I–III.
In this study, we compare pCR, RCB and yAJCC to determine how well these staging 
systems predicted post-treatment recurrence using the I-SPY 1 trial dataset [3, 4]. Our goal 
was to determine strengths of these systems as well as areas in which they could be 
improved, to help guide future refinements of post-neoadjuvant staging.
MATERIALS AND METHODS
Our group has previously published a detailed description of the methods employed in the I-
SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With 
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Imaging and Molecular Analysis) [3, 4]. Briefly, I-SPY 1 was a limited-access cooperative 
group trial for women with locally-advanced (stage II and III) breast cancer treated with 
neoadjuvant, anthracycline-based chemotherapy. The institutional review boards of all 
participating sites approved the I-SPY 1 TRIAL protocol (CALGB150007/150012; ACRIN 
6657). Our primary outcome was recurrence free survival (RFS) according to the STEEP 
criteria.
In the current analysis, we included participants who had completed neoadjuvant 
chemotherapy, undergone definitive surgery, and who had both RCB and yAJCC stages 
determined from their post-treatment surgical resection specimens. We excluded patients 
treated with neoadjuvant or adjuvant trastuzumab because at time of study initiation, 
trastuzumab was given at physician discretion, typically to patients who were felt not to be 
responding to then-standard of care regimens. This lowered the proportion of HER2-positive 
samples in our study population, but there were no other significant differences in pre-
treatment patient characteristics or RFS of our study population compared to the full I-SPY 
1 TRIAL cohort. To evaluate impact of exclusion of patients who received trastuzumab, we 
conducted a separate analysis including these patients; results were not found to differ 
significantly from those presented here.
Pathologists at participating sites evaluated pCR, RCB and yAJCC stage components at the 
time of surgery. PCR was defined as the absence of invasive carcinoma in both breast and 
lymph node tissue. RCB score and class were determined using the MD Anderson Cancer 
Center’s online calculator (http://www3.mdanderson.org/app/medcalc/index.cfm?
pagename=jsconvert3). To standardize measurements across several sites and minimize 
inter-observer variability, all study pathologists were trained on RCB calculation during an 
instruction session at MD Anderson Cancer Center or via an online webinar. The first five 
specimens from each pathologist were centrally re-reviewed.
yAJCC stage was determined using the 7th edition of the AJCC staging guidelines. 
Subgroups (IIA/B, IIIA/B/C) were also calculated, but were not used in the recurrence 
analysis because of insufficient subgroup sample sizes. When nests of tumor cells in fibrotic 
stroma were observed after treatment, the distance over which the tumor nests spread was 
used for measurement of tumor size (ypT).
Recurrence-free survival (RFS) was the primary outcome of interest, and was calculated in 
accordance with STEEP criteria [8]. We constructed Kaplan Meier survival curves to stratify 
patients by yAJCC stage and RCB class overall and within HR/HER2 subtypes, and we 
applied the log-rank test to test for significant curve separation. Patients were removed from 
at-risk groups when they were censored or experienced recurrence or death. We used a Cox 
proportional hazards model to assess clinical and pathological parameters as predictors of 
RFS, and we computed Harrell’s C statistics, a concordance measure used to assess a 
model’s predictive performance, to compare systems. We also adopted recursive partitioning 
to identify variables that best predict RFS. Recursive partitioning is a multivariable analysis 
tool that builds a decision tree that most effectively predicts the outcome of interest (RFS) 
by splitting the total group into subgroups based on input variables. The statistical 
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programming environment R was used to carry out the recursive partitioning, using the rpart 
package. Cox proportional hazards analyses were carried out in STATA version 11.
RESULTS
Study participants
Among the 237 women enrolled in the I-SPY 1 TRIAL, 201 completed neoadjuvant 
chemotherapy and post-treatment surgery, and had both RCB and yAJCC data available for 
analysis. Median age was 48 years (range: 26–68). Excluding patients treated with 
trastuzumab, we analyzed 162 patients (Figure 1). Table 2 summarizes the patients’ pre-
treatment characteristics. Most (51%) had clinical stage II cancers. Most had hormone 
receptor (ER or PR) positive tumors (64%), and 18% had HER2 positive tumors. Median 
follow-up time for patients was 6.7 years. After completing chemotherapy, 37 patients (23%) 
had achieved pCR.
RCB and yAJCC identify patients at high risk of early relapse
Figure 2 shows recurrence free survival (RFS) stratified by RCB class, and Figure 3 shows 
recurrence free survival (RFS) based on yAJCC stage. Patients with pCR (i.e. RCB 0 and 
yAJCC 0) had overall low recurrence rates (92% 5-year RFS), and were at a significantly 
lower risk of recurrence when compared to patients with any amount of residual disease 
(Table 3). In comparison, patients with low to intermediate residual disease (RCB 1 or 2, 
yAJCC 1 or 2) had a ~4-fold increased risk of relapse/death; the increased risk was ~11-fold 
for patients with extensive residual disease (RCB3, yAJCC3). When we compared patients 
with RCB3 to patients with RCB <3, patients with RCB 3 remained significantly more likely 
to recur (RCB 3 vs. RCB 0/1/2: Hazard Ratio = 3.37 (1.96–5.80) p < 0.0001). Similarly, 
patients with yAJCC III had significantly worse RFS than patients with yAJCC <III (yAJCC 
III vs yAJCC 0/I/II: Hazard Ratio = 3.40 (1.99–5.83), p < 0.0001). Both RCB 3 and yAJCC 
III remained significant predictors of high recurrence risk after adjusting for age, clinical 
stage and HR status, both when RCB and yAJCC were stratified into four classes and when 
they were dichotomized (RCB 0/1/2 vs 3 and yAJCC 0/I/II vs III).
TN and HER2+ subtyping improves RCB and yAJCC predictive ability
Both RCB and yAJCC show the strongest association with RFS in patients with “triple-
negative” (HR−/HER2−, abbreviated TN) cancers (Figures 2b and 3b). Conversely, patients 
who had HR+/HER2− tumors had relatively low recurrence rates regardless of RCB or 
yAJCC class, and neither RCB nor yAJCC significantly associate with RFS within this 
subtype (Figure 2c and 3c). Likewise, a comparison of the predictive performances of Cox 
proportional hazard models constructed for all patients vs. within individual subtypes 
suggests that the staging systems tended to predict RFS more effectively when subtype was 
taken into account. This is indicated by higher Harrell’s C statistics (an indicator of a 
model’s predictive ability) for each system within the TN and the HER2+ subtypes versus 
overall, although this effect was not seen in patients with HR+/HER2− tumors (Table 4). 
When we analyzed RCB score as a continuous rather than a discreet variable, the continuous 
score was significantly associated with RFS in all subtypes (Table 5).
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Recursive partitioning selects yAJCC III and RCB 3 as more effective predictors of early 
relapse than subtype
Recursive partitioning was used to identify the optimal way to separate patients based on 
their recurrence-free survival. We included pCR, RCB, yAJCC, age and hormone receptor/
HER2 status as potential variables for the model to use. The model initially separated 
patients by yAJCC, identifying “high-risk” (yAJCC III) and “low-risk” (yAJCC 0/I/II) 
groups. It subsequently separated patients in the high-risk group by receptor status, and the 
low-risk group by whether a pCR was achieved (Figure 4a). In this model, patients who 
were yAJCC III and TN or HER2+ were at significantly higher risk of relapse than all other 
patients (Hazard Ratio: 8.39 (4.41–15.94), p<0.0001). When yAJCC was excluded as an 
input variable, recursive partitioning selected RCB as the optimal variable to identify 
patients who would recur, again separating patients into “high-risk” (RCB 3) and “low-risk” 
(RCB 0/1/2) groups. Like yAJCC, the model subdivided the “high-risk” group based on 
receptor subtype and “low-risk” patients by whether a pCR was achieved (Figure 4b). In this 
model, patients with RCB 3 who were TN or HER2+ were at significantly higher risk of 
early relapse than all other patients (Hazard Ratio: 7.47 (3.83–14.57, p<0.0001).
yAJCC and RCB stages are often discrepant
In 34% (n=55) of patients, RCB and yAJCC staging systems were discrepant (Table 6). 
RCB class was greater than yAJCC in 36 patients, while yAJCC staging was greater than 
RCB in 19 patients. Discrepancies were largely due to unequal weighting of positive lymph 
nodes in the two systems and the weighting of tumor cellularity in RCB, which is not 
incorporated into yAJCC. For 11 patients with discrepant RCB and yAJCC scores, 
pathology slides were available to re-review to qualitatively assess the reasons for the 
discrepancy. Visual examples of features that commonly led to discrepasncy are given in 
Supplemental Figure 1. These images show a cancer with low cellularity but many positive 
nodes that received a higher yAJCC stage than RCB stage (Supplemental Figure 1a–b), and 
also illustrate a tumor with high cellularity and no positive nodes that received an RCB stage 
greater than yAJCC stage (Supplemental Figure 1c).
DISCUSSION
Pathologic response to treatment after neoadjuvant chemotherapy provides valuable 
prognostic information. The goal of this analysis was to compare three commonly used 
staging systems and highlight areas in which these systems differ and could be improved. 
Our analysis revealed three key findings: 1) RCB and yAJCC identify patients at high risk of 
early relapse, 2) predictive ability of these staging systems increases when HR/HER2 
subtype is taken into account, and 3) RCB and yAJCC often produce discrepant results, 
largely driven by differential treatment of lymph nodes and the inclusion of cellularity in 
calculation of RCB. These findings complement a recent, multi-cohort analysis of RCB [17].
In contrast to pCR, our recursive partitioning analysis suggests that a primary utility of RCB 
and yAJCC may be to identify patients with residual tumor who are at highest risk of 
relapse. Specifically, the model identified yAJCC III and (when yAJCC was excluded) RCB 
3 as the primary predictors of relapse.
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By combining receptor subtype and staging system, recursive partitioning was able to 
identify a subset of patients that was at exceptionally high risk of early relapse: patients with 
extensive residual tumor (yAJCC III and/or RCB 3) whose tumors were also TN or HER2+ 
(three-year RFS for patients with yAJCC III and RCB 3 was 27% and 29% respectively 
within these subtypes). Previous analysis has shown that pCR was more effective at 
predicting RFS within receptor subtypes than in all cases combined within the I-SPY 1 
dataset [4]. Our study extends this finding to patients with varying degrees of residual tumor, 
in which both RCB and yAJCC staging systems tend to be more predictive of RFS when 
analyzed by subtype.
The exception to this trend was the HR+/HER2− subtype. The majority of HR+/HER2− 
patients were at either intermediate or high risk for recurrence according to RCB (82% of 
these patients were RCB 2 or 3) and yAJCC (71% of these patients were yAJCC II or III), 
yet patients with this subtype had better RFS than patients with HER2+ or TN cancers. This 
result supports previous analysis suggesting that HR+/HER2− tumors may be intrinsically 
less responsive to chemotherapy [3], and therefore patients with these tumors may be 
predisposed to lower rates of pCR [7] and more extensive residual tumor. However, it is well 
known that patients with HR+/HER2− subtype tumors tend to experience lower rates of 
recurrence than patients with HER2+ or TN tumors, consistent with our results. Notably, 
using a combined analysis of several cohorts, Symmans and colleagues demonstrated that 
RCB did predict RFS among HR+/HER2− patients, including between participants at 
intermediate (RCB 2) and high (RCB 3) predicted risk of relapse [17]. Nonetheless, like in 
our study, Symmans found that a substantial majority (60%) of patients with HR+/HER2− 
disease were classified as RCB 2, suggesting potential need for further methods to stratify 
patients within HR+/HER2− patients.
In contrast to yAJCC, RCB is calculated as a continuous score. Although RCB class was 
specified using cut points that were determined using a unified cohort in which all subtypes 
were represented [16], the continuous score may allow for definition of subtype-specific cut 
points. Although our dataset was not large enough to establish subtype-specific cut points, 
we nevertheless found that within each subtype, continuous RCB score was significantly 
associated with RFS (notably, categorical RCB score was not significantly associated with 
RFS in HR+/HER2− patients). In the future, the ability to define subtype-specific RCB class 
cut points may make RCB particularly valuable as a post-neoadjuvant risk-stratification 
system.
In our dataset, different weighting of lymph nodes and tumor cellularity were the primary 
drivers of discrepancies between RCB and yAJCC. In discrepant cases, if one staging 
system identified the patient as high-risk, then that patient tended to have increased rate of 
early recurrence regardless of how the other system ranked her tumor. This suggests that 
there may be benefit to computing both scores for patients to identify those at highest risk of 
relapse. Sample-size limitations prevented us from defining subsets of patients based on 
nodes or cellularity in which one system out-performed the other. However, as post-
neoadjuvant pathological staging continues to evolve, our results suggest that an avenue to 
improve these systems may be to reevaluate the role of cellularity and number of positive 
lymph nodes, drawing from apparent strengths of RCB and yAJCC, respectively.
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Although pathologic staging using one or more of the systems reviewed here is routinely 
carried out following neoadjuvant chemotherapy, there are known limitations to calculation 
of each of these scores. For RCB, cellularity and overall dimensions of the tumor bed are 
subjective, and the tumor bed can show heterogeneity in response, complicating calculation 
of cellularity and dimensions. In the I-SPY trial, standardized training for pathologists, 
complemented by diagrams and a standard protocol for slide review, were used to ensure 
consistent calculation of cellularity and tumor bed size. For yAJCC, the presence of 
scattered foci of residual tumor in the tumor bed may compromise calculation of residual 
tumor size. Finally, inclusion or exclusion of ductal carcinoma in situ may vary in 
determination of pCR. In our study, presence of residual DCIS in the absence of other 
residual tumor was considered to be pCR, reflecting a typical, but not universal, definition of 
pCR. Although residual ductal carcinoma in situ was found to predict adverse outcomes in 
one recent cohort [18], it has not found to adversely affect outcomes in other studies [9, 11]; 
its impact on outcomes remains a topic of investigation.
The limitations of our analysis include short median follow-up time (6.7 years) and small 
sample size. The short follow-up has the greatest impact on the HR+/HER2− subset, in 
which low overall rates of early relapse limited additional stratification by yAJCC and RCB. 
In addition, trastuzumab became standard of care for HER2+ patients while this study was 
ongoing; prior to then, it was administered at physician discretion. By excluding patients 
who received trastuzumab, we avoided introducing this source of bias into our analysis, but 
future analyses of post-neoadjuvant staging should assess this staging in cohorts in which 
the most up to date chemotherapy guidelines are reflected. To assess the effect of excluding 
patients who received trastuzumab, we conducted an analysis on the complete cohort, 
including these patients (data not shown), and found no significant differences from the 
results we present here. Finally, inter-observer variability in pathologic assessment was not 
addressed in this study, although it has previously been shown to be high among a small 
sample of pathologists evaluating RCB [12]. In summary, we have shown that RCB and 
yAJCC staging systems identify patients who are at highest risk for early recurrence, in 
contrast to pCR, which selects patients at lowest risk for relapse. In addition, our analysis 
suggests that combining pathologic staging with HR/HER2 subtyping further stratifies 
patients’ risk, and that triple negative status combined with high disease burden poses the 
greatest risk to RFS. Continuous RCB score was found to be significantly associated with 
RFS within each subtype, suggesting that distinct risk classification cut points could be 
determined for each subtype to improve RFS predictions. Finally, we found that RCB and 
yAJCC frequently produce discrepant risk predictions, resulting primarily from different 
treatment of lymph nodes and tumor cellularity. Patients with high tumor cellularity may 
particularly benefit from calculation of RCB in addition to routine yAJCC staging. 
Altogether, our findings indicate that tumor cellularity lymph node status and receptor status 
are useful areas of further investigation for evolving post-neoadjuvant tumor staging 
systems.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Consort diagram: patients available for analysis.
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Recurrence-free survival (RFS) based on Residual Cancer Burden (RCB) for all patients (a) 
and by subtype (b–d).
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Recurrence-free survival (RFS) based on American Joint Committee on Cancer (yAJCC) 
stage for all patients (a) and by subtype (b–d).
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Figure 4(a and b). 
Recursive partitioning models of predictors of RFS. Under each branch, the calculated risk 
is listed. Beneath that, the number of patients with a recurrence or death is divided by the 
number of patients within each category. Figure 4b was generated when yAJCC was 
excluded from the model.
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Table 1
Summary of post-neoadjuvant pathologic staging systems.
Staging System Abbreviation Categories Components
American Joint Commitee on Cancer yAJCC 0, I, II (a–b), III (a–c), IV T - tumor size, invasion of local structures
N - nodal metastases
M - distant metastases
Residual Cancer Burden RCB 0, 1, 2, 3 Tumor size
Tumor cellularity
Nodal metastases
Pathologic Complete Response pCR Absent, present Any residual tumor
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Table 2
Patient characteristics.
Pre-Surgery Characteristics n (%)
Total patients analyzed 162
Median age (years) (range) 48 (26–68)
Pre-menopausal 77 (48)
Race Caucasian 123 (76)
African American 28 (17)
Asian 6 (4)
Other/Not specified 5 (3)
Clinical tumor size (cm) (range) 7 (0–18)
Histologic grade Grade I 14 (9)
Grade II 72 (44)
Grade III 73 (45)
Indeterminate 3 (2)






Hormone and HER2 receptors HER2+ 29 (18)
HR+/HER2− 87 (54)
HR−/HER2− 46 (28)
Neoadjuvant treatment AC only 11 (7)
AC + T 150 (92)
AC + T + Other 1 (1)
AC + T + Other 1 (1)
Post-Surgery Patient Characteristics
Histologic grade Grade I 20 (12)
Grade II 64 (40)
Grade III 32 (20)
No invasive disease present or not reported 46 (28)
pCR (also RCB class 0, yAJCC stage 0) 37 (23)
RCB Class 1 13 (8)
2 75 (46)
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Pre-Surgery Characteristics n (%)
3 37 (23)
yAJCC Stage I 33 (20)
II 52 (32)
 IIA 31 (19)
 IIB 21 (13)
III 40 (25)
 IIIA 25 (15)
 IIIB 2 (1)
 IIIC 13 (8)
Adjuvant systemic therapy Any hormonal therapy 135 (83)
Aromatase Inhibitor 73 (45)
Tamoxifen 62 (38)
Ovarian suppression 14 (9)
Ovarian ablation 6 (4)
Abbreviations: HR = hormone receptor; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; 
AC = doxorubicin/cyclophosphamide; T = paclitaxel; pCR = pathologic complete response; yAJCC = American Joint Committee on Cancer post-
neoadjuvant staging; RCB = residual cancer burden.
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Table 3
Significance of key variables in Cox modeling of RFS.
Univariate Multivariate*
Hazard Ratio (CI) p-value Hazard Ratio (CI) p-value
pCR
No pCR Relative to pCR 5.97 (1.86 – 19.12) 0.003 9.18 (2.75 – 30.62) <0.0001
RCB
Four Classes (Relative to RCB 0)
RCB 1 4.49 (1.07 – 18.79) 0.04 6.66 (1.57 – 28.24) 0.01
RCB 2 4.31 (1.29 – 14.36) 0.02 7.95 (2.29 – 27.61) <0.0001
RCB 3 11.07 (3.32 – 36.91) <0.0001 24.08 (6.50 – 89.27) <0.0001
Dichotomized (RCB 3 relative to RCB 0/1/2) 3.37 (1.96 – 5.80) <0.0001 4.02 (2.18 – 7.54) <0.0001
yAJCC
Four Classes (Relative to yAJCC 0)
yAJCC I 4.13 (1.14 – 15.01) 0.03 5.84 (1.59 – 21.44) 0.01
yAJCC II 4.34 (1.27 – 14.82) 0.02 11.83 (3.19 – 43.88) <0.0001
yAJCC III 10.94 (3.29 – 36.37) <0.0001 22.57 (6.02 – 84.60) <0.0001
Dichotomized (yAJCC III relative to yAJCC 0/I/II) 3.40 (1.99 – 5.83) <0.0001 3.27 (1.73–6.17) <0.0001
**
Adjusted for clinical stage (III/Inflammatory vs. I/II), age and HR status
Abbreviations: pCR = pathologic complete response; yAJCC = American Joint Committee on Cancer post-neoadjuvant staging; RCB = residual 
cancer burden; RFS = recurrence-free survival; CI = confidence interval; HR = hormone receptor.













Campbell et al. Page 19
Table 4
Comparison of pCR, yAJCC and RCB as predictors of RFS by subtype.
Staging Method Hazard Ratio (95% CI) (Relative to pCR/RCB/yAJCC 0) Harrell’s C
Overall
yAJCC 0.683
I 4.13 (1.14 – 15.01)
II 4.34 (1.27 – 14.82)
III 10.94 (3.29 – 36.37)
RCB 0.677
1 4.49 (1.07 – 18.79)
2 4.31 (1.29 – 14.36)
3 11.07 (3.32 – 36.91)
no pCR: 5.97 (1.86 – 19.12) 0.597
HR+/HER2− (n=87 d=26)*
yAJCC 0.640
I >25 (n/a† )
II >25 (n/a† )
III >25 (n/a† )
RCB 0.641
1 >25 (n/a† )
2 >25 (n/a† )
3 >25 (n/a† )
no pCR >25 (n/a† ) 0.552
HER2+ (n=29 d=11)*
yAJCC 0.713
I 18.06 (1.98 – 164.77)
II 3.39 (0.31 – 37.40)
III 20.87 (2.29 – 190.48)
RCB 0.725
1 11.75 (1.21 – 114.30)
2 6.54 (0.73 – 58.55)
3 22.01 (2.09 – 232.25)
no pCR 9.65 (1.23–75.7) 0.705
TN (n=46 d=17)*
yAJCC 0.802
I 1.73 (0.24 – 12.27)
II 4.81 (0.88 – 26.32)
III 21.24 (4.49–100.55)
RCB 0.774
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Staging Method Hazard Ratio (95% CI) (Relative to pCR/RCB/yAJCC 0) Harrell’s C
1 <0.0001 (n/a‡)
2 3.65 (0.74 – 18.10)
3 16.92 (3.59 – 79.66)
no pCR 6.04 (1.38–26.49) 0.669
HER2+ or TN (n=75 d=24)*
yAJCC 0.764
I 4.45 (1.11 – 17.80)
II 4.08 (1.02 – 16.31)
III 20.56 (5.78 – 73.18)
RCB 0.746
1 5.18 (1.05 – 25.69)
2 4.54 (1.25 – 16.51)
3 18.02 (4.98 – 65.21)
no pCR 7.1 (2.14–23.55) 0.678
*
n=total number of patients in category, d=number of patients who experienced recurrence and/or death in category.
†
CI could not be calculated because no relapses/deaths occurred in the pCR group.
‡
CI could not be calculated because no relapses/deaths occurred in the RCB1 group.
Abbreviations: pCR = pathologic complete response; yAJCC = American Joint Committee on Cancer post-neoadjuvant staging; RCB = residual 
cancer burden; RFS = recurrence-free survival; CI = confidence interval; HR = hormone receptor; HER2 = human epidermal growth factor receptor 
2; TN = triple negative.
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Table 5




Continuous RCB Index** <0.0001
HR+HER2− (n=79)
RCB Class* 0.109
Continuous RCB Index** 0.0053
HER2+ (n=17)
RCB Class* 0.0137
Continuous RCB Index** 0.0091
*
Evaluated with log rank p tests of a Kaplan-Meier curve
**
Evaluated with Wald test p-value from a univariate Cox model











































































































































































































































































Breast Cancer Res Treat. Author manuscript; available in PMC 2018 August 01.
